BioLineRx Ltd.
BLRX
$3.85
$0.112.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -94.36% | -96.28% | 144.77% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -94.36% | -96.28% | 144.77% | -- | -- |
| Cost of Revenue | -91.97% | -97.66% | 64.92% | -- | -- |
| Gross Profit | -94.84% | -95.91% | 410.83% | -- | -- |
| SG&A Expenses | -97.40% | -87.20% | -29.43% | -27.90% | 16.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.65% | -77.34% | -10.47% | -16.40% | 12.62% |
| Operating Income | 60.11% | 50.41% | 73.28% | 56.41% | 41.78% |
| Income Before Tax | -914.05% | 836.64% | 77.05% | 63.66% | 102.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -914.05% | 836.64% | 77.05% | 63.66% | 102.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -914.05% | 836.64% | 77.05% | 63.66% | 102.61% |
| EBIT | 60.11% | 50.41% | 73.28% | 56.41% | 41.78% |
| EBITDA | 59.85% | 43.29% | 82.79% | 62.53% | 45.49% |
| EPS Basic | -525.00% | 483.33% | 81.40% | 71.51% | 101.99% |
| Normalized Basic EPS | -433.33% | 450.00% | 78.57% | 72.22% | 102.38% |
| EPS Diluted | -525.00% | 483.33% | 81.40% | 71.51% | 101.99% |
| Normalized Diluted EPS | -433.33% | 450.00% | 78.57% | 72.22% | 102.38% |
| Average Basic Shares Outstanding | 97.87% | 104.10% | 21.30% | 29.11% | 29.75% |
| Average Diluted Shares Outstanding | 97.87% | 104.10% | 21.30% | 29.11% | 29.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |